Bimekizumab is a biologic medicine used to treat adults with moderate to severe plaque psoriasis. It is a human monoclonal antibody that targets interleukin-17A (IL-17A). Bimekizumab works by blocking the action of IL-17A, a protein involved in inflammation. This can reduce the symptoms of plaque psoriasis, including red, itchy, and scaly patches on the skin. Bimekizumab is administered as an injection under the skin (subcutaneous) every 4 weeks. Common side effects include injection site reactions, upper respiratory tract infections, and headache.
Bimekizumab, sold under the brand name Bimzelx, is a humanized monoclonal antibody medication used to treat several chronic inflammatory conditions, including:
- Plaque psoriasis: This is the most common form of psoriasis, a condition that causes red, scaly patches to form on the skin.
- Psoriatic arthritis: This is an inflammatory arthritis that can affect people with psoriasis.
- Axial spondyloarthritis: This is a type of inflammatory arthritis that affects the spine.
- Ankylosing spondylitis: This is a form of axial spondylitis that can cause the spine to fuse together.
Bimekizumab works by blocking the activity of interleukin-17 (IL-17), a protein that plays a role in the immune system. By blocking IL-17, bimekizumab can help to reduce inflammation and improve symptoms of these conditions.
Bimekizumab is given as an injection under the skin. The usual dose is 315 milligrams once every four weeks. Bimekizumab is a relatively new medication, and it is still being studied to determine its long-term safety and efficacy.